The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Pharmacotherapy for Nicotine Dependence
Open accessAbstract
Approximately 50% of long-term cigarette smokers die prematurely from the adverse effects of smoking, including on cancer, cardiovascular disease, lung disease, or other illness. This risk can be substantially reduced by smoking cessation, with greater benefits occurring the earlier in the smoking career that cessation occurs. However, cessation provides benefits at any stage, including after the onset of smoking-related disease, by improving the prognosis and quality of life. Clinicians can have a significant impact on reducing tobacco use by their patients by following the US Public Health Service Clinical Practice Guidelines. Proven strategies include structured methods of advising cigarette smokers to quit and guidance to facilitate their efforts, as well as the use of various pharmacotherapies. Pharmacotherapies for tobacco dependence include nicotine replacement medications in the form of gum, transdermal patch, lozenge, sublingual tablet, nasal spray, and vapor inhaler formulations. The only nonnicotine medication that has been approved by the US Food and Drug Administration is bupropion. Combination therapies, long-term medication therapies, and harm reduction strategies may further improve outcome with approved medications. Further, new medications such as varenicline and rimonabant are likely to reach tobacco users who are refractory to current treatments. Increasing the treatment options, increasing availability, and reducing the perceived cost of these medications may have an additional public health impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738 · cited 1×
“In fact, time to the first cigarette and number of cigarettes per day are the two strongest predictors of nicotine dependence level.(18) Two medical disorders are now widely recognized to comprise what is more generally termed tobacco addiction or dependence: 1) nicotine dependence, which is the disorder of maladaptiv…”
BackgroundActual Causes of Death in the United States, 2000
Mokdad, A. H. (2004) · JAMA · doi:10.1001/jama.291.10.1238 · Cited by 5,211
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“It has also been shown that bupropion combined with nicotine replacement medications may increase cessation rates relative to bupropion alone.(73) The recommended and maximum dose of bupropion is 300 mg/day, given as 150 mg twice daily.”
BackgroundAntidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
First lapses to smoking: Within-subjects analysis of real-time reports.
Shiffman, S., Paty, J. A., Gnys, M., Kassel, J. A., & Hickcox, M. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.64.2.366 · Cited by 745
Benowitz, N. L., Porchet, H., Sheiner, L., & Jacob, P. (1988) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1988.107 · Cited by 619
Predicting Smoking Cessation: Who Will Quit With and Without the Nicotine Patch
Kenford, S. L. (1994) · JAMA · doi:10.1001/jama.271.8.589 · Cited by 405
Cohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00018 · Cited by 396
Nortriptyline and Cognitive-Behavioral Therapy in the Treatment of Cigarette Smoking
Hall, S. M., Reus, V. I., Muñoz, R. F., Sees, K. L., Humfleet, G., Hartz, D. T., Frederick, S., & Triffleman, E. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.683 · Cited by 385
Nicotine Medications for Smoking Cessation
Henningfield, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331807 · Cited by 352 · cited 1×
“Transdermal patches deliver nicotine more slowly than acute NRT formulations, although nicotine plasma concentrations can become higher during the day with patch use than with acute NRT use, especially if the patient does not use the acute NRT product as many times during the day as recommended.(22,38) Importantly, ni…”
BackgroundSelf-citationEfficacy of a nicotine lozenge for smoking cessation
Shiffman, S., Dresler, C. M., Hajek, P., Gilburt, S. J. A., Targett, D. A., & Strahs, K. R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.11.1267 · Cited by 265 · cited 1×
“A newer nicotine lozenge, available in 2- and 4-mg formulations since 2002, is the most recent NRT to receive approval in the United States for smoking cessation.(52) Unlike nicotine gum in which the smoker chooses the dose based on number of cigarettes, the indication for the lozenge allocates smokers to the 2- or 4-…”
BackgroundThe effect of bupropion on nicotine craving and withdrawal
Shiffman, S., Johnston, J. A., Khayrallah, M., Elash, C. A., Gwaltney, C. J., Paty, J. A., Gnys, M., Evoniuk, G., & DeVeaugh-Geiss, J. (2000) · Psychopharmacology · doi:10.1007/s002130050022 · Cited by 259
Hajek, P., West, R., Foulds, J., Nilsson, F., Burrows, S., & Meadow, A. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.17.2033 · Cited by 255 · cited 1×
“For this reason, compliance with patch therapy tends to be higher than for other NRT products.(37) Transdermal patches deliver nicotine more slowly than acute NRT formulations, although nicotine plasma concentrations can become higher during the day with patch use than with acute NRT use, especially if the patient doe…”
BackgroundCryan, J. F., Bruijnzeel, A. W., Skjei, K. L., & Markou, A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1445-7 · Cited by 223 · cited 1×
“One study found that low doses of bupropion reduced the rewarding effects of nicotine and the affective and somatic symptoms of withdrawal.(89) Another study examined the effects of bupropion (5 to 40 mg/kg) on the reinforcing properties of nicotine and food in rats under two different schedules of reinforcement.”
BackgroundNicotine Replacement Therapy: What Has Been Accomplished - Can We Do Better?
Benowitz, N. L. (1993) · Drugs · doi:10.2165/00003495-199345020-00001 · Cited by 174
Extended nortriptyline and psychological treatment for cigarette smoking
Hall, S. M., Humfleet, G. L., Reus, V. I., Muñoz, R. F., & Cullen, J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2100 · Cited by 158
The financial implications of coverage of smoking cessation treatment by managed care organizations
Warner, K. E., Mendez, D., & Smith, D. G. (2004) · INQUIRY: The Journal of Health Care Organization, Provision, and Financing · doi:10.5034/inquiryjrnl_41.1.57 · Cited by 49
Heavy Smokers, Smoking Cessation, and Clonidine: Results of a Double-blind, Randomized Trial
Glassman, A. H. (1988) · JAMA · doi:10.1001/jama.1988.03720190031026 · cited 1×
“For example, one study of heavy smokers who had failed in previous quit attempts found that those treated with clonidine had twice the rate of abstinence as those treated with placebo at the end of the 4-week treatment.(106) This effect continued through the 6-month follow up.”
Cited by
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,464
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., & Lancaster, T. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub3 · Cited by 721
Nicotine replacement therapy versus control for smoking cessation
Hartmann-Boyce, J., Chepkin, S. C., Ye, W., Bullen, C., & Lancaster, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub5 · Cited by 697
The relevance and treatment of cue-induced cravings in tobacco dependence
Ferguson, S. G., & Shiffman, S. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2008.06.005 · Cited by 361
Cigarette smoking: An undertreated risk factor for cardiovascular disease
Erhardt, L. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.007 · Cited by 286
Metadata
- Authors
- Henningfield, J. E., Fant, R. V., Buchhalter, A. R., & Stitzer, M. L.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2005-09-01
- Volume
- 55
- Issue
- 5
- Pages
- 281-299
- ISSN
- 0007-9235 (ISSN-L)
- OpenAlex
- W2142225862
- Cited by
- 227
- References
- 18
- FWCI
- 15.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.